Abstract：
Acute myeloid leukemia (AML) is a fatal blood malignancy. With the development of immunotherapy, particularly chimeric antigen receptor T cells (CAR-T), the treatment of AML has undergone a significant change. Despite its advantages, CAR-T still faces a number of limitations and challenges while treating AML. Finding novel targets, altering the structure of CAR to increase efficacy while lowering side effects, and using double-target CAR and logic circuits are typical examples of key to answer these problems. With the advancement of gene editing technology, gene editing of tumor cells or normal cells to create therapeutic effects has grown in popularity. Additionally, the combination of multiple drugs is routinely used to address some of the obstacles and difficulties associated with CAR-T therapy. The review\'s primary goal was to summarize recent strategies and developments of CAR-T therapy for AML.
摘要：
■急性髓细胞性白血病（AML）是一种致命的血液恶性肿瘤。随着免疫治疗的发展,特别是嵌合抗原受体T细胞（CAR-T），AML的治疗发生了重大变化。尽管有其优势,CAR-T在治疗AML时仍然面临许多限制和挑战。寻找新的目标，改变CAR的结构以增加功效，同时降低副作用，使用双目标CAR和逻辑电路是解决这些问题的关键的典型例子。随着基因编辑技术的进步,对肿瘤细胞或正常细胞进行基因编辑以产生治疗效果已经越来越受欢迎。此外,多种药物的联合应用通常用于解决与CAR-T治疗相关的一些障碍和困难.该综述的主要目的是总结CAR-T治疗AML的最新策略和进展。
